Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 16/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17419037 | 0.88 | KDM4E (0.42) | NPC1RAB9AALDH1A1FFAR1FFAR4 | |
| SCHEMBL17418596 | 0.85 | FFAR1 (0.54) | NPC1RAB9AFFAR1KDM1AFFAR4 | |
| SCHEMBL17418612 | 0.83 | FFAR1 (0.41) | FFAR1FFAR4 | |
| SCHEMBL17418945 | 0.83 | FFAR1 (0.54) | NPC1RAB9AFFAR1KDM1AFFAR4 | |
| SCHEMBL17418907 | 0.80 | FFAR1 (0.37) | FFAR1 | |
| SCHEMBL17418604 | 0.74 | FFAR1 (0.41) | NPC1RAB9AFFAR1FFAR4 | |
| SCHEMBL17418840 | 0.74 | USP7 (0.41) | NPC1RAB9AFFAR1KDM1AFFAR4 | |
| SCHEMBL17418933 | 0.73 | FFAR1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL17431571 | 0.72 | FFAR1 (0.56) | FFAR1 | |
| SCHEMBL17418530 | 0.71 | FFAR1 (0.56) | FFAR1KDM1AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688642-B2 | Substituted pyrazines as GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| WO-2016007714-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007714-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009662-A1 | PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | NPC1 1669/4885RAB9A 2845/4885ALDH1A1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.